Document Detail

Potential target antigens for immunotherapy in human pancreatic cancer.
MedLine Citation:
PMID:  17320278     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To be effective and selective, immunotherapy ideally targets specifically tumor cells and spares normal tissues. Identification of tumor specific antigens is a prerequisite to establish an effective immunotherapy. Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms. Cancer Testis antigens (CT) are antigens shared by a variety of malignant tumors, but not by normal tissues with the exception of germ cells in testis. Restricted expression in neoplastic tissues and inherent immunogenic features make CT antigens ideal for use in immunotherapy. We analyzed the expression of a selected panel of nine CT antigens that have been proven to elicit an efficient immunogenic response in other malignancies. In addition we analyzed the expression of HERV-K-MEL, an immunogenic antigen of viral origin. METHODS: Pancreatic adenocarcinoma tumor samples (n=130) were obtained intraoperatively, control tissues (n=23) were collected from cadaveric donor and from patients with chronic pancreatitis. Tumor-associated antigen expression of MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, LAGE-1, NY-ESO-1, SCP-1, SSX-2, SSX-4 and HERV-K-MEL was assessed by PCR. Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues. RESULTS: Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples. SSX-4 was found positive in 30% of cases, SCP-1 in 19% and HERV-K-MEL in 23% of cases. No expression of CT antigens was found in non-malignant pancreatic tissue with the exception of SSX-4 and and SSX-2. CONCLUSIONS: Fifty two percentage of the analyzed tissues expressed at least one CT antigen. The concomitant expression of SSX-4 in both malignant and non-malignant pancreatic tissue is a new finding which may raise concerns for immunotherapy. However, HERV-K-MEL is expressed with a relatively high prevalence and may be a candidate for specific immunotherapy in a large subgroup of pancreatic cancer patients. This study advocates the analysis of patients with regard to their immunogenic profile before the onset of antigen-specific immunotherapy.
F H Schmitz-Winnenthal; L V Galindo-Escobedo; D Rimoldi; W Geng; P Romero; M Koch; J Weitz; R Krempien; A G Niethammer; P Beckhove; M W Buchler; K Z'graggen
Related Documents :
2124308 - Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueou...
8917348 - Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor acti...
25203118 - Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes ...
6428708 - Kaposi's sarcoma and autoimmune thrombocytopenia.
7923768 - Immunoassay with recombinant trypanosoma cruzi antigens potentially useful for screenin...
1782668 - Immunoelectron microscopic localization of cell surface antigens on rat hepatocytes det...
Publication Detail:
Type:  Journal Article     Date:  2007-02-22
Journal Detail:
Title:  Cancer letters     Volume:  252     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-05-30     Completed Date:  2007-10-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  290-8     Citation Subset:  IM    
Department of General Surgery, University Hospital of Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / immunology,  therapy*
Antigens, Neoplasm / immunology*
Azacitidine / administration & dosage
Base Sequence
DNA Primers
Pancreatic Neoplasms / immunology,  therapy*
Reg. No./Substance:
0/Antigens, Neoplasm; 0/DNA Primers; 320-67-2/Azacitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Irreversible papillitis and ophthalmoparesis as a presenting manifestation of neurobrucellosis.
Next Document:  PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bla...